Beatica AB

Prof. Dr. Helena Danielson
Box 567
SE-75122 Uppsala
Sweden

Beactica is a specialist drug discovery company, utilizing its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. Founded in 2006 based on research carried out at Uppsala University, Beactica have unique expertise in Surface Plasmon Resonance (SPR)-based drug discovery for small molecule programmes. Our exceptional scientific team has unrivalled experience in applying SPR technology to solve problems during lead discovery and optimization.

Beactica’s role in Neurocypres is to apply its unique discovery platform on selected cys-loop receptors to identify and optimize selective lead compounds that show a high development potential. Beactica’s fragment-based approach works also when protein crystallization is not possible. This enables us to work with wider range of protein targets. For more information please visit www.beactica.com. Next partner >